The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cellsHui Shi, Lihong Ye, Leilei Li et al.|Cancer Letters|2016Cited by 51
Bispecific antibody targeting CD40 and HER2 potentiates therapeutic efficacy by reprogramming macrophages within the tumour microenvironmentNa Li, Ruonan Li, Qiongqiong Ma et al.|Clinical and Translational Medicine|2025Cited by 0